Galimoto yozindikira - t

Mbiri Yachitukuko Pagalimoto - T

Kukula kwa Galimoto - Mankhwala a Tre cell amatha kutsatiridwa kubwerera ku 1989, pomwe adaloza G ndi asayansi atatu adafunsa koyamba za "galimoto". Kenako, mu 2008, gulu la Fred Cancen Institutes linagwiritsa ntchito ma cell a mgalimoto kuti agwiritse ntchito B - Cell lymphoma, kuwonetsa chitetezo cha njira yochizira. In 2010, the first successful case of CD19-targeting CAR-T therapy for B-cell-associated non-Hodgkin lymphoma was reported in the United States. Kenako mu 2011, pulofesa Carl Phunziro la June ku Yunivesite ya Pennsylvania lidapita patsogolo kwambiri, ndipo nkhani yopambana ya Emily, idayambitsa galimoto Ty telec mankhwala ataphulika. Mu 2017, US Chakudya cha US ndi mankhwala osokoneza bongo (FDA) adavomereza kuloledwa kwa malonda a Cell Tral Trance Gymria, yomwe idalemba nthawi ya malonda a magalimoto T. M'chaka chomwechi, mgalimoto yachiwiri, TAMCimitsa cell mankhwala, idavomerezedwanso kutsatsa malonda. Mu 2020, FDA AKHALIDWA ATSOGOLO ACHITA TU - Mankhwala othandizira te cell tecartus. Mu 2021, FDA yovomerezeka kagalimoto kawiri - TAMYANIOTHI ndi Abecma ndi Abecma, pokonzanso B - cell lymhoma ndi milpoma, motsatana. M'chaka chomwechi, mdedwe wochokera ku China adavomerezanso kulembetsa kwa magalimoto awiri a galimoto kuchokera ku Axi - Celdi "

Mu 2022, FDA yovomerezeka kulembetsa kwa Carvykti, galimoto - mgalimoto ya cell contrasing B Cell Pale Exumation Antigen (BCMA) yovomerezeka kapena yodziwika bwino.

Pakadali pano, mankhwala agalimoto T adalowa m'nthawi ya khansa ya Immunotherapy ndikutsegula lokongola m'dziko lapansi.

Galimoto - t cell mankhwala

Car T celpy mankhwala, imadziwikanso kuti chimbo antigen t cenesi immunotherapy (galimoto - Izi zimawathandiza kuzindikira mwachindunji maselo otupa ndikulowetsa maselo amenewo kuti azitha kuchiza matendawa.

Iit kalasi Ind Kalasi Yachipatala Kalasi ya malonda

Galimoto - t